Skip to main content
Top
Published in: BMC Psychiatry 1/2013

Open Access 01-12-2013 | Review

The nature of relapse in schizophrenia

Authors: Robin Emsley, Bonginkosi Chiliza, Laila Asmal, Brian H Harvey

Published in: BMC Psychiatry | Issue 1/2013

Login to get access

Abstract

Background

Multiple relapses characterise the course of illness in most patients with schizophrenia, yet the nature of these episodes has not been extensively researched and clinicians may not always be aware of important implications.

Methods

We critically review selected literature regarding the nature and underlying neurobiology of relapse.

Results

Relapse rates are very high when treatment is discontinued, even after a single psychotic episode; a longer treatment period prior to discontinuation does not reduce the risk of relapse; many patients relapse soon after treatment reduction and discontinuation; transition from remission to relapse may be abrupt and with few or no early warning signs; once illness recurrence occurs symptoms rapidly return to levels similar to the initial psychotic episode; while most patients respond promptly to re-introduction of antipsychotic treatment after relapse, the response time is variable and notably, treatment failure appears to emerge in about 1 in 6 patients. These observations are consistent with contemporary thinking on the dopamine hypothesis, including the aberrant salience hypothesis.

Conclusions

Given the difficulties in identifying those at risk of relapse, the ineffectiveness of rescue medications in preventing full-blown psychotic recurrence and the potentially serious consequences, adherence and other factors predisposing to relapse should be a major focus of attention in managing schizophrenia. The place of antipsychotic treatment discontinuation in clinical practice and in placebo-controlled clinical trials needs to be carefully reconsidered.
Literature
1.
go back to reference Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, et al: Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999, 56: 241-247. 10.1001/archpsyc.56.3.241.CrossRefPubMed Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, et al: Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999, 56: 241-247. 10.1001/archpsyc.56.3.241.CrossRefPubMed
2.
go back to reference Kane JM: Treatment strategies to prevent relapse and encourage remission. J Clin Psychiatry. 2007, 68 (Suppl 14): 27-30.PubMed Kane JM: Treatment strategies to prevent relapse and encourage remission. J Clin Psychiatry. 2007, 68 (Suppl 14): 27-30.PubMed
3.
go back to reference Wyatt RJ: Research in schizophrenia and the discontinuation of antipsychotic medications. Schizophr Bull. 1997, 23: 3-9. 10.1093/schbul/23.1.3.CrossRefPubMed Wyatt RJ: Research in schizophrenia and the discontinuation of antipsychotic medications. Schizophr Bull. 1997, 23: 3-9. 10.1093/schbul/23.1.3.CrossRefPubMed
4.
go back to reference Lieberman JA, Alvir JM, Koreen A, Geisler S, Chakos M, Sheitman B, et al: Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology. 1996, 14: 13S-21S. 10.1016/0893-133X(95)00200-W.CrossRefPubMed Lieberman JA, Alvir JM, Koreen A, Geisler S, Chakos M, Sheitman B, et al: Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology. 1996, 14: 13S-21S. 10.1016/0893-133X(95)00200-W.CrossRefPubMed
5.
go back to reference Alvarez-Jimenez M, Priede A, Hetrick SE, Bendall S, Killackey E, Parker AG, et al: Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr Res. 2012, 139: 116-128. 10.1016/j.schres.2012.05.007.CrossRefPubMed Alvarez-Jimenez M, Priede A, Hetrick SE, Bendall S, Killackey E, Parker AG, et al: Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr Res. 2012, 139: 116-128. 10.1016/j.schres.2012.05.007.CrossRefPubMed
6.
go back to reference Coldham EL, Addington J, Addington D: Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand. 2002, 106: 286-290. 10.1034/j.1600-0447.2002.02437.x.CrossRefPubMed Coldham EL, Addington J, Addington D: Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand. 2002, 106: 286-290. 10.1034/j.1600-0447.2002.02437.x.CrossRefPubMed
7.
go back to reference Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P: A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011, 168: 603-609. 10.1176/appi.ajp.2011.10081224.CrossRefPubMed Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P: A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011, 168: 603-609. 10.1176/appi.ajp.2011.10081224.CrossRefPubMed
8.
go back to reference Miller BJ: A review of second-generation antipsychotic discontinuation in first-episode psychosis. J Psychiatr Pract. 2008, 14: 289-300. 10.1097/01.pra.0000336756.65308.83.CrossRefPubMed Miller BJ: A review of second-generation antipsychotic discontinuation in first-episode psychosis. J Psychiatr Pract. 2008, 14: 289-300. 10.1097/01.pra.0000336756.65308.83.CrossRefPubMed
9.
go back to reference Miller BJ, Bodenheimer C, Crittenden K: Second-Generation Antipsychotic Discontinuation in First Episode Psychosis: An Updated Review. Clin Psychopharmacol Neurosci. 2011, 9: 45-53.CrossRefPubMedPubMedCentral Miller BJ, Bodenheimer C, Crittenden K: Second-Generation Antipsychotic Discontinuation in First Episode Psychosis: An Updated Review. Clin Psychopharmacol Neurosci. 2011, 9: 45-53.CrossRefPubMedPubMedCentral
10.
go back to reference Emsley R, Oosthuizen PP, Koen L, Niehaus DJ, Martinez L: Symptom Recurrence Following Intermittent Treatment in First Episode Schizophrenia Successfully Treated for Two Years. In J Clin Psychiatry. 2012, In press Emsley R, Oosthuizen PP, Koen L, Niehaus DJ, Martinez L: Symptom Recurrence Following Intermittent Treatment in First Episode Schizophrenia Successfully Treated for Two Years. In J Clin Psychiatry. 2012, In press
11.
go back to reference Emsley R, Nuamah I, Hough D, Gopal S: Treatment response after relapse in a placebo controlled maintenance trial in schizophrenia. Schizophr Res. 2012, 138 (1): 29-34. 10.1016/j.schres.2012.02.030. Epub 2012 Mar 23CrossRefPubMed Emsley R, Nuamah I, Hough D, Gopal S: Treatment response after relapse in a placebo controlled maintenance trial in schizophrenia. Schizophr Res. 2012, 138 (1): 29-34. 10.1016/j.schres.2012.02.030. Epub 2012 Mar 23CrossRefPubMed
12.
go back to reference Emsley R, Oosthuizen PP, Koen L, Niehaus DJ, Martinez L: Comparison of Treatment Response in Second Episode Versus First Episode Schizophrenia. J Clin Psychopharmaco. 2013, 33 (1): 80-83. 10.1097/JCP.0b013e31827bfcc1.CrossRef Emsley R, Oosthuizen PP, Koen L, Niehaus DJ, Martinez L: Comparison of Treatment Response in Second Episode Versus First Episode Schizophrenia. J Clin Psychopharmaco. 2013, 33 (1): 80-83. 10.1097/JCP.0b013e31827bfcc1.CrossRef
13.
go back to reference Moller HJ, von Ziersen D, et al: Course and outcome of schizophrenia. Schizophrenia. 1995, Oxford: Blackwell, 127- Moller HJ, von Ziersen D, et al: Course and outcome of schizophrenia. Schizophrenia. 1995, Oxford: Blackwell, 127-
14.
go back to reference Kane JM, Jeste DV, Barnes TR: Tardive dyskinesia: A task force report of the American Psychiatric Association. 1992, Washington, D.C: American Psychiatric Association, Ref Type: Report Kane JM, Jeste DV, Barnes TR: Tardive dyskinesia: A task force report of the American Psychiatric Association. 1992, Washington, D.C: American Psychiatric Association, Ref Type: Report
15.
go back to reference Meltzer HY: Neuroleptic withdrawal in schizophrenic patients. An idea whose time has come. Arch Gen Psychiatry. 1995, 52: 200-202.PubMed Meltzer HY: Neuroleptic withdrawal in schizophrenic patients. An idea whose time has come. Arch Gen Psychiatry. 1995, 52: 200-202.PubMed
16.
go back to reference Newcomer JW: Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007, 68 (Suppl 1): 20-27.PubMed Newcomer JW: Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007, 68 (Suppl 1): 20-27.PubMed
17.
go back to reference Bostwick JR, Guthrie SK, Ellingrod VL: Antipsychotic-induced hyperprolactinemia. Pharmacotherapy. 2009, 29: 64-73. 10.1592/phco.29.1.64.CrossRefPubMed Bostwick JR, Guthrie SK, Ellingrod VL: Antipsychotic-induced hyperprolactinemia. Pharmacotherapy. 2009, 29: 64-73. 10.1592/phco.29.1.64.CrossRefPubMed
18.
go back to reference Correll CU, Schenk EM: Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008, 21: 151-156. 10.1097/YCO.0b013e3282f53132.CrossRefPubMed Correll CU, Schenk EM: Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008, 21: 151-156. 10.1097/YCO.0b013e3282f53132.CrossRefPubMed
19.
go back to reference Perkins DO, Gu H, Weiden PJ, McEvoy JP, Hamer RM, Lieberman JA: Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry. 2008, 69: 106-113. 10.4088/JCP.v69n0114.CrossRefPubMed Perkins DO, Gu H, Weiden PJ, McEvoy JP, Hamer RM, Lieberman JA: Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry. 2008, 69: 106-113. 10.4088/JCP.v69n0114.CrossRefPubMed
20.
go back to reference Gilbert PL, Harris MJ, McAdams LA, Jeste DV: Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry. 1995, 52: 173-188. 10.1001/archpsyc.1995.03950150005001.CrossRefPubMed Gilbert PL, Harris MJ, McAdams LA, Jeste DV: Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry. 1995, 52: 173-188. 10.1001/archpsyc.1995.03950150005001.CrossRefPubMed
21.
go back to reference Gitlin M, Nuechterlein K, Subotnik KL, Ventura J, Mintz J, Fogelson DL, et al: Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry. 2001, 158: 1835-1842. 10.1176/appi.ajp.158.11.1835.CrossRefPubMed Gitlin M, Nuechterlein K, Subotnik KL, Ventura J, Mintz J, Fogelson DL, et al: Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry. 2001, 158: 1835-1842. 10.1176/appi.ajp.158.11.1835.CrossRefPubMed
22.
go back to reference Chen EY, Hui CL, Lam MM, Chiu CP, Law CW, Chung DW, et al: Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. BMJ. 2010, 341: c4024-10.1136/bmj.c4024.CrossRefPubMedPubMedCentral Chen EY, Hui CL, Lam MM, Chiu CP, Law CW, Chung DW, et al: Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. BMJ. 2010, 341: c4024-10.1136/bmj.c4024.CrossRefPubMedPubMedCentral
23.
go back to reference Boonstra G, Burger H, Grobbee DE, Kahn RS: Antipsychotic prophylaxis is needed after remission from a first psychotic episode in schizophrenia patients: results from an aborted randomised trial. Int J Psychiatry Clin Pract. 2011, 15: 128-134. 10.3109/13651501.2010.534801.CrossRefPubMed Boonstra G, Burger H, Grobbee DE, Kahn RS: Antipsychotic prophylaxis is needed after remission from a first psychotic episode in schizophrenia patients: results from an aborted randomised trial. Int J Psychiatry Clin Pract. 2011, 15: 128-134. 10.3109/13651501.2010.534801.CrossRefPubMed
24.
go back to reference Kane JM, Rifkin A, Quitkin F, Nayak D, Ramos-Lorenzi J: Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. Arch Gen Psychiatry. 1982, 39: 70-73. 10.1001/archpsyc.1982.04290010048009.CrossRefPubMed Kane JM, Rifkin A, Quitkin F, Nayak D, Ramos-Lorenzi J: Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. Arch Gen Psychiatry. 1982, 39: 70-73. 10.1001/archpsyc.1982.04290010048009.CrossRefPubMed
25.
go back to reference Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering R, Wiersma D: Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry. 2007, 68: 654-661. 10.4088/JCP.v68n0502.CrossRefPubMed Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering R, Wiersma D: Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry. 2007, 68: 654-661. 10.4088/JCP.v68n0502.CrossRefPubMed
26.
go back to reference Crow TJ, MacMillan JF, Johnson AL, Johnstone EC: A randomised controlled trial of prophylactic neuroleptic treatment. In Br J Psychiatry. 1986, 148: 120-127. 10.1192/bjp.148.2.120.CrossRef Crow TJ, MacMillan JF, Johnson AL, Johnstone EC: A randomised controlled trial of prophylactic neuroleptic treatment. In Br J Psychiatry. 1986, 148: 120-127. 10.1192/bjp.148.2.120.CrossRef
27.
go back to reference Gaebel W, Riesbeck M, Wolwer W, Klimke A, Eickhoff M, Von WM, et al: Relapse prevention in first-episode schizophrenia–maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry. 2011, 72: 205-218. 10.4088/JCP.09m05459yel.CrossRefPubMed Gaebel W, Riesbeck M, Wolwer W, Klimke A, Eickhoff M, Von WM, et al: Relapse prevention in first-episode schizophrenia–maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry. 2011, 72: 205-218. 10.4088/JCP.09m05459yel.CrossRefPubMed
28.
go back to reference Takeuchi H, Suzuki T, Uchida H, Watanabe K, Mimura M: Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms. Schizophr Res. 2012, 134: 219-225. 10.1016/j.schres.2011.11.021.CrossRefPubMed Takeuchi H, Suzuki T, Uchida H, Watanabe K, Mimura M: Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms. Schizophr Res. 2012, 134: 219-225. 10.1016/j.schres.2011.11.021.CrossRefPubMed
29.
go back to reference Gefvert O, Eriksson B, Persson P, Helldin L, Bjorner A, Mannaert E, et al: Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. Int J Neuropsychopharmacol. 2005, 8: 27-36. 10.1017/S1461145704004924.CrossRefPubMed Gefvert O, Eriksson B, Persson P, Helldin L, Bjorner A, Mannaert E, et al: Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. Int J Neuropsychopharmacol. 2005, 8: 27-36. 10.1017/S1461145704004924.CrossRefPubMed
30.
go back to reference Moncrieff J: Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand. 2006, 114: 3-13.CrossRefPubMed Moncrieff J: Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand. 2006, 114: 3-13.CrossRefPubMed
31.
go back to reference Chouinard G, Jones BD: Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry. 1980, 137: 16-21.CrossRefPubMed Chouinard G, Jones BD: Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry. 1980, 137: 16-21.CrossRefPubMed
32.
go back to reference Birchwood M, Smith J, MacMillan F, Hogg B, Prasad R, Harvey C, et al: Predicting relapse in schizophrenia: the development and implementation of an early signs monitoring system using patients and families as observers, a preliminary investigation. Psychol Med. 1989, 19: 649-656. 10.1017/S0033291700024247.CrossRefPubMed Birchwood M, Smith J, MacMillan F, Hogg B, Prasad R, Harvey C, et al: Predicting relapse in schizophrenia: the development and implementation of an early signs monitoring system using patients and families as observers, a preliminary investigation. Psychol Med. 1989, 19: 649-656. 10.1017/S0033291700024247.CrossRefPubMed
33.
go back to reference Yung AR, McGorry PD: The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr Bull. 1996, 22: 353-370. 10.1093/schbul/22.2.353.CrossRefPubMed Yung AR, McGorry PD: The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr Bull. 1996, 22: 353-370. 10.1093/schbul/22.2.353.CrossRefPubMed
34.
go back to reference Bustillo J: Buchanan RW. Carpenter WT Jr: Prodromal symptoms vs. early warning signs and clinical action in schizophrenia. Schizophr Bull. 1995, 21: 553-559.PubMed Bustillo J: Buchanan RW. Carpenter WT Jr: Prodromal symptoms vs. early warning signs and clinical action in schizophrenia. Schizophr Bull. 1995, 21: 553-559.PubMed
35.
go back to reference Norman RM, Malla AK: Prodromal symptoms of relapse in schizophrenia: a review. Schizophr Bull. 1995, 21: 527-539. 10.1093/schbul/21.4.527.CrossRefPubMed Norman RM, Malla AK: Prodromal symptoms of relapse in schizophrenia: a review. Schizophr Bull. 1995, 21: 527-539. 10.1093/schbul/21.4.527.CrossRefPubMed
36.
go back to reference Gaebel W, Riesbeck M: Revisiting the relapse predictive validity of prodromal symptoms in schizophrenia. Schizophr Res. 2007, 95: 19-29. 10.1016/j.schres.2007.06.016.CrossRefPubMed Gaebel W, Riesbeck M: Revisiting the relapse predictive validity of prodromal symptoms in schizophrenia. Schizophr Res. 2007, 95: 19-29. 10.1016/j.schres.2007.06.016.CrossRefPubMed
37.
go back to reference Gaebel W, Frick U, Kopcke W, Linden M, Muller P, Muller-Spahn F, et al: Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse?. Br J Psychiatry Suppl. 1993, 21: 8-12.PubMed Gaebel W, Frick U, Kopcke W, Linden M, Muller P, Muller-Spahn F, et al: Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse?. Br J Psychiatry Suppl. 1993, 21: 8-12.PubMed
39.
go back to reference Henmi Y: Prodromal symptoms of relapse in schizophrenic outpatients: retrospective and prospective study. Jpn J Psychiatry Neurol. 1993, 47: 753-775.PubMed Henmi Y: Prodromal symptoms of relapse in schizophrenic outpatients: retrospective and prospective study. Jpn J Psychiatry Neurol. 1993, 47: 753-775.PubMed
40.
go back to reference Tarrier N, Barrowclough C, Bamrah JS: Prodromal signs of relapse in schizophrenia. Soc Psychiatry Psychiatr Epidemiol. 1991, 26: 157-161.PubMed Tarrier N, Barrowclough C, Bamrah JS: Prodromal signs of relapse in schizophrenia. Soc Psychiatry Psychiatr Epidemiol. 1991, 26: 157-161.PubMed
41.
go back to reference Gleeson JF, Rawlings D, Jackson HJ, McGorry PD: Early warning signs of relapse following a first episode of psychosis. Schizophr Res. 2005, 80: 107-111. 10.1016/j.schres.2005.07.019.CrossRefPubMed Gleeson JF, Rawlings D, Jackson HJ, McGorry PD: Early warning signs of relapse following a first episode of psychosis. Schizophr Res. 2005, 80: 107-111. 10.1016/j.schres.2005.07.019.CrossRefPubMed
42.
go back to reference Birchwood M, Spencer E: Early intervention in psychotic relapse. Clin Psychol Rev. 2001, 21: 1211-1226. 10.1016/S0272-7358(01)00105-2.CrossRefPubMed Birchwood M, Spencer E: Early intervention in psychotic relapse. Clin Psychol Rev. 2001, 21: 1211-1226. 10.1016/S0272-7358(01)00105-2.CrossRefPubMed
43.
go back to reference Emsley R, Medori R, Koen L, Oosthuizen PP, Niehaus DJ, Rabinowitz J: Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J Clin Psychopharmacol. 2008, 28: 210-213. 10.1097/JCP.0b013e318167269d.CrossRefPubMed Emsley R, Medori R, Koen L, Oosthuizen PP, Niehaus DJ, Rabinowitz J: Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J Clin Psychopharmacol. 2008, 28: 210-213. 10.1097/JCP.0b013e318167269d.CrossRefPubMed
44.
go back to reference Wyatt RJ: Neuroleptics and the natural course of schizophrenia. Schizophr Bull. 1991, 17: 325-351. 10.1093/schbul/17.2.325.CrossRefPubMed Wyatt RJ: Neuroleptics and the natural course of schizophrenia. Schizophr Bull. 1991, 17: 325-351. 10.1093/schbul/17.2.325.CrossRefPubMed
45.
go back to reference Lieberman JA, Jody D, Geisler S, Alvir J, Loebel A, Szymanski S, et al: Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry. 1993, 50: 369-376. 10.1001/archpsyc.1993.01820170047006.CrossRefPubMed Lieberman JA, Jody D, Geisler S, Alvir J, Loebel A, Szymanski S, et al: Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry. 1993, 50: 369-376. 10.1001/archpsyc.1993.01820170047006.CrossRefPubMed
46.
go back to reference Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T: Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry. 2005, 62: 975-983. 10.1001/archpsyc.62.9.975.CrossRefPubMed Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T: Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry. 2005, 62: 975-983. 10.1001/archpsyc.62.9.975.CrossRefPubMed
47.
go back to reference McEvoy JP, Hogarty GE, Steingard S: Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry. 1991, 48: 739-745.PubMed McEvoy JP, Hogarty GE, Steingard S: Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry. 1991, 48: 739-745.PubMed
48.
go back to reference Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC: Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. III. Relapse postponement or relapse prevention? The implications for long-term outcome. Br J Psychiatry. 1985, 146: 474-480. 10.1192/bjp.146.5.474.CrossRefPubMed Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC: Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. III. Relapse postponement or relapse prevention? The implications for long-term outcome. Br J Psychiatry. 1985, 146: 474-480. 10.1192/bjp.146.5.474.CrossRefPubMed
49.
go back to reference Glovinsky D, Kirch DG, Wyatt RJ: Early antipsychotic response to resumption of neuroleptics in drug-free chronic schizophrenic patients. Biol Psychiatry. 1992, 31: 968-970. 10.1016/0006-3223(92)90124-I.CrossRefPubMed Glovinsky D, Kirch DG, Wyatt RJ: Early antipsychotic response to resumption of neuroleptics in drug-free chronic schizophrenic patients. Biol Psychiatry. 1992, 31: 968-970. 10.1016/0006-3223(92)90124-I.CrossRefPubMed
50.
go back to reference Wyatt RJ, Henter ID, Bartko JJ: The long-term effects of placebo in patients with chronic schizophrenia. Biol Psychiatry. 1999, 46: 1092-1105. 10.1016/S0006-3223(99)00227-9.CrossRefPubMedPubMedCentral Wyatt RJ, Henter ID, Bartko JJ: The long-term effects of placebo in patients with chronic schizophrenia. Biol Psychiatry. 1999, 46: 1092-1105. 10.1016/S0006-3223(99)00227-9.CrossRefPubMedPubMedCentral
51.
go back to reference Levine SZ, Leucht S: Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories. Biol Psychiatry. 2010, 68: 86-92. 10.1016/j.biopsych.2010.01.012.CrossRefPubMed Levine SZ, Leucht S: Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories. Biol Psychiatry. 2010, 68: 86-92. 10.1016/j.biopsych.2010.01.012.CrossRefPubMed
53.
go back to reference Zipursky RB, Reilly JL, Murray RM: The myth of schizophrenia as a progressive brain disease. Schizophr Bull. 2012, Epub ahead of print Zipursky RB, Reilly JL, Murray RM: The myth of schizophrenia as a progressive brain disease. Schizophr Bull. 2012, Epub ahead of print
54.
go back to reference Wiersma D, Nienhuis FJ, Slooff CJ, Giel R: Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. Schizophr Bull. 1998, 24: 75-85. 10.1093/oxfordjournals.schbul.a033315.CrossRefPubMed Wiersma D, Nienhuis FJ, Slooff CJ, Giel R: Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. Schizophr Bull. 1998, 24: 75-85. 10.1093/oxfordjournals.schbul.a033315.CrossRefPubMed
55.
go back to reference Kapur S, Mamo D: Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2003, 27: 1081-1090. 10.1016/j.pnpbp.2003.09.004.CrossRefPubMed Kapur S, Mamo D: Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2003, 27: 1081-1090. 10.1016/j.pnpbp.2003.09.004.CrossRefPubMed
56.
go back to reference Howes OD, Kapur S: The dopamine hypothesis of schizophrenia: version III–the final common pathway. Schizophr Bull. 2009, 35: 549-562. 10.1093/schbul/sbp006.CrossRefPubMedPubMedCentral Howes OD, Kapur S: The dopamine hypothesis of schizophrenia: version III–the final common pathway. Schizophr Bull. 2009, 35: 549-562. 10.1093/schbul/sbp006.CrossRefPubMedPubMedCentral
57.
go back to reference Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A, et al: The Nature of Dopamine Dysfunction in Schizophrenia and What This Means for Treatment: Meta-analysis of Imaging Studies. Arch Gen Psychiatry. 2012, 69 (8): 776-786. 10.1001/archgenpsychiatry.2012.169.CrossRefPubMedPubMedCentral Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A, et al: The Nature of Dopamine Dysfunction in Schizophrenia and What This Means for Treatment: Meta-analysis of Imaging Studies. Arch Gen Psychiatry. 2012, 69 (8): 776-786. 10.1001/archgenpsychiatry.2012.169.CrossRefPubMedPubMedCentral
58.
go back to reference Kapur S: Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry. 2003, 160: 13-23. 10.1176/appi.ajp.160.1.13.CrossRefPubMed Kapur S: Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry. 2003, 160: 13-23. 10.1176/appi.ajp.160.1.13.CrossRefPubMed
59.
go back to reference Agid O, Kapur S, Arenovich T, Zipursky RB: Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry. 2003, 60: 1228-1235. 10.1001/archpsyc.60.12.1228.CrossRefPubMed Agid O, Kapur S, Arenovich T, Zipursky RB: Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry. 2003, 60: 1228-1235. 10.1001/archpsyc.60.12.1228.CrossRefPubMed
60.
go back to reference Leucht S, Busch R, Hamann J, Kissling W, Kane JM: Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry. 2005, 57: 1543-1549. 10.1016/j.biopsych.2005.02.023.CrossRefPubMed Leucht S, Busch R, Hamann J, Kissling W, Kane JM: Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry. 2005, 57: 1543-1549. 10.1016/j.biopsych.2005.02.023.CrossRefPubMed
61.
go back to reference Emsley R, Rabinowitz J, Medori R: Time course for antipsychotic treatment response in first-episode schizophrenia. Am J Psychiatry. 2006, 163: 743-745. 10.1176/appi.ajp.163.4.743.CrossRefPubMed Emsley R, Rabinowitz J, Medori R: Time course for antipsychotic treatment response in first-episode schizophrenia. Am J Psychiatry. 2006, 163: 743-745. 10.1176/appi.ajp.163.4.743.CrossRefPubMed
64.
go back to reference Leonard BE, Schwarz M, Myint AM: The metabolic syndrome in schizophrenia: is inflammation a contributing cause?. J Psychopharmacol. 2012, 26: 33-41. 10.1177/0269881111431622.CrossRefPubMed Leonard BE, Schwarz M, Myint AM: The metabolic syndrome in schizophrenia: is inflammation a contributing cause?. J Psychopharmacol. 2012, 26: 33-41. 10.1177/0269881111431622.CrossRefPubMed
65.
go back to reference Drzyzga L, Obuchowicz E, Marcinowska A, Herman ZS: Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immun. 2006, 20: 532-545. 10.1016/j.bbi.2006.02.002.CrossRefPubMed Drzyzga L, Obuchowicz E, Marcinowska A, Herman ZS: Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immun. 2006, 20: 532-545. 10.1016/j.bbi.2006.02.002.CrossRefPubMed
66.
go back to reference Moller M, Du Preez JL, Viljoen FP, Berk M, Emsley R, Harvey BH: Social isolation rearing induces mitochondrial, immunological, neurochemical and behavioural deficits in rats, and is reversed by clozapine or N-acetyl cysteine. Brain Behavior and Immunity. 10.1016/j.bbi.2012.12.011. Epub ahead of print Moller M, Du Preez JL, Viljoen FP, Berk M, Emsley R, Harvey BH: Social isolation rearing induces mitochondrial, immunological, neurochemical and behavioural deficits in rats, and is reversed by clozapine or N-acetyl cysteine. Brain Behavior and Immunity. 10.1016/j.bbi.2012.12.011. Epub ahead of print
67.
go back to reference McAllister CG, van Kammen DP, Rehn TJ, Miller AL, Gurklis J, Kelley ME, et al: Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am J Psychiatry. 1995, 152: 1291-1297.CrossRefPubMed McAllister CG, van Kammen DP, Rehn TJ, Miller AL, Gurklis J, Kelley ME, et al: Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am J Psychiatry. 1995, 152: 1291-1297.CrossRefPubMed
68.
go back to reference Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B: Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011, 70: 663-671. 10.1016/j.biopsych.2011.04.013.CrossRefPubMedPubMedCentral Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B: Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011, 70: 663-671. 10.1016/j.biopsych.2011.04.013.CrossRefPubMedPubMedCentral
69.
go back to reference Miller BJ, Gassama B, Sebastian D, Buckley P, Mellor A: Meta-Analysis of Lymphocytes in Schizophrenia: Clinical Status and Antipsychotic Effects. Biol Psychiatry. 2012, doi:10.1016/j.biopsych.2012.09.007. doi:pii: S0006-3223(12):00779-2. Miller BJ, Gassama B, Sebastian D, Buckley P, Mellor A: Meta-Analysis of Lymphocytes in Schizophrenia: Clinical Status and Antipsychotic Effects. Biol Psychiatry. 2012, doi:10.1016/j.biopsych.2012.09.007. doi:pii: S0006-3223(12):00779-2.
70.
go back to reference Harvey BH, McEwen BS, Stein DJ: Neurobiology of antidepressant withdrawal: implications for the longitudinal outcome of depression. Biol Psychiatry. 2003, 54: 1105-1117. 10.1016/S0006-3223(03)00528-6.CrossRefPubMed Harvey BH, McEwen BS, Stein DJ: Neurobiology of antidepressant withdrawal: implications for the longitudinal outcome of depression. Biol Psychiatry. 2003, 54: 1105-1117. 10.1016/S0006-3223(03)00528-6.CrossRefPubMed
71.
go back to reference Andreassen OA, Jorgensen HA: Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats, implications for tardive dyskinesia. Prog Neurobiol. 2000, 61: 525-531. 10.1016/S0301-0082(99)00064-7.CrossRefPubMed Andreassen OA, Jorgensen HA: Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats, implications for tardive dyskinesia. Prog Neurobiol. 2000, 61: 525-531. 10.1016/S0301-0082(99)00064-7.CrossRefPubMed
72.
go back to reference Naidu PS, Kulkarni SK: Excitatory mechanisms in neuroleptic-induced vacuous chewing movements (VCMs): possible involvement of calcium and nitric oxide. Behav Pharmacol. 2001, 12: 209-216. 10.1097/00008877-200105000-00006.CrossRefPubMed Naidu PS, Kulkarni SK: Excitatory mechanisms in neuroleptic-induced vacuous chewing movements (VCMs): possible involvement of calcium and nitric oxide. Behav Pharmacol. 2001, 12: 209-216. 10.1097/00008877-200105000-00006.CrossRefPubMed
73.
go back to reference Nel A, Harvey BH: Haloperidol-induced dyskinesia is associated with striatal NO synthase suppression: reversal with olanzapine. Behav Pharmacol. 2003, 14: 251-255. 10.1097/00008877-200305000-00010.CrossRefPubMed Nel A, Harvey BH: Haloperidol-induced dyskinesia is associated with striatal NO synthase suppression: reversal with olanzapine. Behav Pharmacol. 2003, 14: 251-255. 10.1097/00008877-200305000-00010.CrossRefPubMed
74.
go back to reference Harvey BH, Joubert C, du Preez JL, Berk M: Effect of chronic N-acetyl cysteine administration on oxidative status in the presence and absence of induced oxidative stress in rat striatum. Neurochem Res. 2008, 33: 508-517. 10.1007/s11064-007-9466-y.CrossRefPubMed Harvey BH, Joubert C, du Preez JL, Berk M: Effect of chronic N-acetyl cysteine administration on oxidative status in the presence and absence of induced oxidative stress in rat striatum. Neurochem Res. 2008, 33: 508-517. 10.1007/s11064-007-9466-y.CrossRefPubMed
75.
go back to reference Harvey BH, Bester A: Withdrawal-associated changes in peripheral nitrogen oxides and striatal cyclic GMP after chronic haloperidol treatment. Behav Brain Res. 2000, 111: 203-211. 10.1016/S0166-4328(00)00156-X.CrossRefPubMed Harvey BH, Bester A: Withdrawal-associated changes in peripheral nitrogen oxides and striatal cyclic GMP after chronic haloperidol treatment. Behav Brain Res. 2000, 111: 203-211. 10.1016/S0166-4328(00)00156-X.CrossRefPubMed
76.
go back to reference Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, et al: N-acetyl cysteine as a glutathione precursor for schizophrenia–a double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 2008, 64: 361-368. 10.1016/j.biopsych.2008.03.004.CrossRefPubMed Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, et al: N-acetyl cysteine as a glutathione precursor for schizophrenia–a double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 2008, 64: 361-368. 10.1016/j.biopsych.2008.03.004.CrossRefPubMed
77.
go back to reference van Harten PN, Hoek HW, Matroos GE, Koeter M, Kahn RS: Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curacao Extrapyramidal Syndromes Study III. Am J Psychiatry. 1998, 155: 565-567.CrossRefPubMed van Harten PN, Hoek HW, Matroos GE, Koeter M, Kahn RS: Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curacao Extrapyramidal Syndromes Study III. Am J Psychiatry. 1998, 155: 565-567.CrossRefPubMed
78.
go back to reference Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S: "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci. 2007, 27: 2979-2986. 10.1523/JNEUROSCI.5416-06.2007.CrossRefPubMed Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S: "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci. 2007, 27: 2979-2986. 10.1523/JNEUROSCI.5416-06.2007.CrossRefPubMed
79.
go back to reference Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, et al: Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012, 379: 2063-2071. 10.1016/S0140-6736(12)60239-6.CrossRefPubMed Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, et al: Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012, 379: 2063-2071. 10.1016/S0140-6736(12)60239-6.CrossRefPubMed
80.
go back to reference Konopaske GT, Dorph-Petersen KA, Sweet RA, Pierri JN, Zhang W, Sampson AR, et al: Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys. Biol Psychiatry. 2008, 63: 759-765. 10.1016/j.biopsych.2007.08.018.CrossRefPubMed Konopaske GT, Dorph-Petersen KA, Sweet RA, Pierri JN, Zhang W, Sampson AR, et al: Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys. Biol Psychiatry. 2008, 63: 759-765. 10.1016/j.biopsych.2007.08.018.CrossRefPubMed
Metadata
Title
The nature of relapse in schizophrenia
Authors
Robin Emsley
Bonginkosi Chiliza
Laila Asmal
Brian H Harvey
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2013
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/1471-244X-13-50

Other articles of this Issue 1/2013

BMC Psychiatry 1/2013 Go to the issue